Entrectinib (Rozlytrek), the other one approved ROS1 TKI, has been simultaneously approved for the treatment of advanced ROS1‐positive NSCLC and neurotrophic tyrosine receptor kinase (NTRK) gene fusion‐positive solid tumor, including NSCLC in August 2019. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.